Abstract
Purpose of Review
To review the clinical and polysomnographic features of the sleep disorder occurring in the recently described anti-IgLON5 disease. The hallmark of the disease is the presence of antibodies against IgLON5, a neural cell adhesion molecule of unknown function. The disease presents a robust HLA association, and the neuropathological examination shows a novel neuronal tauopathy with predominant hypothalamic and brainstem involvement.
Recent Findings
Most patients (> 80%) present sleep-related vocalizations with movements and behaviors and sleep-disordered breathing. Polysomnographic studies show (1) a complex NREM sleep parasomnia at sleep initiation characterized by undifferentiated NREM or poorly structured N2 sleep with sleep-talking or mumbling, and simple or finalistic movements followed by normal periods of N3 or N2 NREM sleep, (2) REM sleep behavior disorder (RBD), and (3) obstructive sleep apnea with stridor. The last two features appear mainly in periods where NREM sleep normalizes.
Summary
Identification of the anti-IgLON5 sleep disorder is important to suspect the disease. The combination of abnormal NREM sleep initiation, followed by normal periods of NREM sleep and RBD, represents a novel parasomnia.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
•• Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–86. In this paper the disease is identified and described for first time.
•• Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017;88:1736–43. The clinical presentation of the disease is described in detail in a series of 22 patients.
•• Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016;132:531–43. The neuropathological features of the disease are described in detail and neuropathological criteria for anti-IgLON5 disease are defined.
van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger KP, et al. The clinical spectrum of Caspr2 antibody-associated disease. Neurology. 2016;87:521–8.
Höglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32:853–64.
• Högl B, Heidbreder A, Santamaria J, Graus F, Poewe W. IgLON5 autoimmunity and abnormal behaviours during sleep. Lancet. 2015;385:1590. Report of the first patient after the initial description of the disease.
Bahtz R, Teegen B, Borowski K, Probst C, Blöcker IM, Fechner K, et al. Autonatibodies against IgLON5: two new cases. J Neuroimmunol. 2014;275:8.
Schröder JB, Melzer N, Ruck T, et al. Isolated dysphagia as initial sign of anti-IgLON5 syndrome. Neurol Neuroimmunol Neuroinflamm. 2016;4(1):e302.
Haitao R, Yingmai Y, Yan H, Fei H, Xia L, Honglin H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016;300:9–10.
Bonello M, Jacob A, Ellul MA, Barker E, Parker R, Jefferson S, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e383.
Haitao R, Huiqin L, Tao Q, Xunzhe Y, Xiaoqiu S, Wei L, et al. Autoimmune encephalitis associated with vitiligo? J Neuroimmunol. 2017;310:14–6.
Wenninger S. Expanding the clinical Spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017;4:337–9.
• Honorat JA, Lomorowski L, Josephs KA, et al. IgLON5 antibody. Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017;4(5):e385. Description of another series of 20 patients with antibodies against IgLON5.
• Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm. 2015;2:e136. Additional description of a patient with anti-IgLON5 antibodies and progressive disease course.
• Brüggemann N, Wandinger KP, Gaig C, Sprenger A, Junghanns K, Helmchen C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord. 2016;31:762–4. Description of a patient with atypical clinical features.
Montojo MT, Piren V, Benkhadra F, et al. Mimicking progressive supranuclear palsy and causing Tako-Tsubo syndrome: a case report on IgLON5 encephalopathy [abstract]. Mov Disord. 2015;30(Suppl 1):710.
Iranzo A, Santamaría J. Severe obstructive sleep apnea/hypopnea mimicking REM sleep behavior disorder. Sleep. 2005;28:203–6.
Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al. The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG). Sleep Med. 2006;7:175–83.
Mahowald MW, Schenck CH. Status dissociatus: a perspective on states of being. Sleep. 1991;14:69–79.
Montagna P, Lugaresi E. Agrypnia Excitata: a generalized overactivity syndrome and a useful concept in the neurophysiopathology of sleep. Clin Neurophysiol. 2002;113:552–60.
Gaig C, Iranzo A, Santamarí J, Dalmau J, Graus F. Sleep disorder associated with antibodies to IgLON5: parasomnia or agrypnia?—Authors’ reply. Lancet Neurol. 2014;13:864–5.
Baiardi S, Provini F, Avoni P, Pasquinelli M, Liguori R. Immunotherapy of oneiric stupor in Morvan syndrome: efficacy documented by actigraphy. Neurology. 2015;84:2457–9.
Dumitrascu O, Schenck CH, Applebee G, Attarian H. Parasomnia overlap disorder: a distinct pathophysiologic entity or a variant of rapid eye movement sleep behavior disorder? A case series. Sleep Med. 2013;14:1217–20.
Cagnin A, Mariotto S, Fiorini M, Gaule M, Bonetto N, Tagliapietra M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related taupathy. J Clin Alzheimer’s Dis. 2017;59:13–20.
Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation. 2016;13(1):226.
Acknowledgments
We thank Dr. Ellen Gelpi, Institute of Neurology, Medical University of Vienna, for her help in the design of Fig. 2.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Carles Gaig, Alex Iranzo, and Joan Santamaria each declare no potential conflicts of interest. Francesc Graus received a licensing fee from Euroimmun for the use of IgLON5 as an autoantibody test.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Sleep
Rights and permissions
About this article
Cite this article
Gaig, C., Iranzo, A., Santamaria, J. et al. The Sleep Disorder in Anti-lgLON5 Disease. Curr Neurol Neurosci Rep 18, 41 (2018). https://doi.org/10.1007/s11910-018-0848-0
Published:
DOI: https://doi.org/10.1007/s11910-018-0848-0